查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1876008

结合疫苗：全球市场份额和排名、总收入和需求预测（2025-2031年）

Conjugate Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 107 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024年全球结合疫苗市场规模估计为106.4亿美元，预计到2031年将成长至132.24亿美元，在2025年至2031年的预测期内，复合年增长率为3.2%。

本报告从跨境产业布局、资本配置模式、区域经济相互依存以及供应链重组等方面，对近期有关结合疫苗的关税调整和国际战略反制措施进行了全面评估。

疫苗透过诱导身体对抗原产生免疫反应来预防疾病。抗原是细菌或病毒的外来成分，能被免疫系统辨识。结合疫苗的设计理念是将弱抗原与强抗原结合，后者作为载体，使免疫系统对弱抗原产生更强的免疫反应。

结合疫苗市场正经历显着成长，主要驱动力来自全球对感染疾病预防日益增长的关注，尤其是在婴儿童和老年人群体中。结合疫苗透过将弱抗原与强载体蛋白连接来增强免疫反应，已被证明对B型流感嗜血桿菌（Hib）、肺炎球菌和脑膜炎球菌病菌感染具有高效性。各国政府的免疫规划和公共卫生倡议，尤其是在新兴经济体，正在推动疫苗接种覆盖率的提高，从而刺激市场需求。此外，全球疫苗免疫联盟（GAVI）、世界卫生组织（WHO）和联合国儿童基金会（UNICEF）等国际卫生组织的加大投入，以及人们对早期接种疫苗重要性的认识不断提高，也进一步推动了疫苗的普及。疫苗研发领域的技术进步，例如改进的结合方法和新型载体蛋白的开发，使得生产更有效、保护更广泛的疫苗成为可能，从而促进了疫苗创新和市场扩张。

然而，结合疫苗市场面临许多挑战。高昂的研发和生产成本，尤其是多效价疫苗，可能会限制低收入地区的可近性和可负担性。严格的监管要求和漫长的临床试验週期会延缓产品核可，并对新参与企业和中小型生物技术公司构成障碍。偏远和欠发达地区的低温运输物流和储存要求也带来了额外的挑战，并可能影响疫苗的分发和效力。由于错误讯息和公众对免疫规划缺乏信任而导致的疫苗犹豫，也对市场成长构成日益增长的风险。此外，来自mRNA疫苗和蛋白质次单元疫苗等替代疫苗技术的竞争，从长远来看可能会降低人们对结合疫苗平台的兴趣。应对这些挑战需要国际合作，以改善供应链，增加对研究和公共卫生基础设施的投入，并加强对疫苗安全性和有效性的社区教育。

本报告旨在按地区/国家、类型和最终用户对全球结合疫苗市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以销售量（百万支）和收入（百万美元）为单位，对结合疫苗市场规模、估计值和预测进行了呈现，基准年为2024年，并涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定结合疫苗业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Pfizer
  • GSK
  • Sanofi
  • Merck
  • Walvax Biotechnology
  • Royal（Wuxi）Bio-Pharmaceutical
  • Bharat Biotech
  • Zhifei Biologic
  • Beijing Minhai Biotechnology
  • SinoPharma

按类型分類的细分市场

  • Hib疫苗
  • 脑膜炎双球菌疫苗
  • 肺炎链球菌疫苗
  • 其他的

最终使用者群体

  • 儿童
  • 成人

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Conjugate Vaccine was estimated to be worth US$ 10640 million in 2024 and is forecast to a readjusted size of US$ 13224 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Conjugate Vaccine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

The conjugate vaccine market is experiencing significant growth, primarily driven by the increasing global focus on preventing infectious diseases, especially among infants, children, and the elderly. Conjugate vaccines, which link a weak antigen to a strong carrier protein to enhance immune response, have proven highly effective against diseases like Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal infections. Government immunization programs and public health initiatives-particularly in emerging economies-are expanding vaccine coverage, thereby fueling market demand. Additionally, rising investments from global health organizations (such as GAVI, WHO, and UNICEF), along with growing awareness of the importance of early immunization, are further boosting uptake. Technological advancements in vaccine development, including improved conjugation methods and novel carrier proteins, are enabling the production of more effective and broad-spectrum vaccines, supporting innovation and market expansion.

However, the conjugate vaccine market also faces notable challenges. High development and production costs, particularly for multivalent vaccines, can limit affordability and access in low-income regions. Stringent regulatory requirements and lengthy clinical trial timelines can delay product approvals, creating barriers for new entrants and smaller biotech firms. Cold chain logistics and storage requirements pose additional challenges in remote or underdeveloped areas, potentially impacting vaccine distribution and efficacy. Vaccine hesitancy, fueled by misinformation and lack of public trust in immunization programs, also poses a growing risk to market growth. Moreover, competition from alternative vaccine technologies, such as mRNA or protein subunit vaccines, may shift focus away from conjugate platforms in the long term. Addressing these challenges will require international collaboration to improve supply chains, expand funding for research and public health infrastructure, and enhance community education on vaccine safety and effectiveness.

This report aims to provide a comprehensive presentation of the global market for Conjugate Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Conjugate Vaccine by region & country, by Type, and by End Users.

The Conjugate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Million Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Conjugate Vaccine.

Market Segmentation

By Company

  • Pfizer
  • GSK
  • Sanofi
  • Merck
  • Walvax Biotechnology
  • Royal (Wuxi) Bio-Pharmaceutical
  • Bharat Biotech
  • Zhifei Biologic
  • Beijing Minhai Biotechnology
  • SinoPharma

Segment by Type

  • Hib Vaccine
  • Meningococcal Vaccine
  • Pneumococcal Vaccine
  • Others

Segment by End Users

  • Children
  • Adult

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by End Users, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Conjugate Vaccine in country level. It provides sigmate data by Type, and by End Users for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Conjugate Vaccine Product Introduction
  • 1.2 Global Conjugate Vaccine Market Size Forecast
    • 1.2.1 Global Conjugate Vaccine Sales Value (2020-2031)
    • 1.2.2 Global Conjugate Vaccine Sales Volume (2020-2031)
    • 1.2.3 Global Conjugate Vaccine Sales Price (2020-2031)
  • 1.3 Conjugate Vaccine Market Trends & Drivers
    • 1.3.1 Conjugate Vaccine Industry Trends
    • 1.3.2 Conjugate Vaccine Market Drivers & Opportunity
    • 1.3.3 Conjugate Vaccine Market Challenges
    • 1.3.4 Conjugate Vaccine Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Conjugate Vaccine Players Revenue Ranking (2024)
  • 2.2 Global Conjugate Vaccine Revenue by Company (2020-2025)
  • 2.3 Global Conjugate Vaccine Players Sales Volume Ranking (2024)
  • 2.4 Global Conjugate Vaccine Sales Volume by Company Players (2020-2025)
  • 2.5 Global Conjugate Vaccine Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Conjugate Vaccine Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Conjugate Vaccine Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Conjugate Vaccine
  • 2.9 Conjugate Vaccine Market Competitive Analysis
    • 2.9.1 Conjugate Vaccine Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Conjugate Vaccine Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Conjugate Vaccine as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Hib Vaccine
    • 3.1.2 Meningococcal Vaccine
    • 3.1.3 Pneumococcal Vaccine
    • 3.1.4 Others
  • 3.2 Global Conjugate Vaccine Sales Value by Type
    • 3.2.1 Global Conjugate Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Conjugate Vaccine Sales Value, by Type (2020-2031)
    • 3.2.3 Global Conjugate Vaccine Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Conjugate Vaccine Sales Volume by Type
    • 3.3.1 Global Conjugate Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Conjugate Vaccine Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Conjugate Vaccine Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Conjugate Vaccine Average Price by Type (2020-2031)

4 Segmentation by End Users

  • 4.1 Introduction by End Users
    • 4.1.1 Children
    • 4.1.2 Adult
  • 4.2 Global Conjugate Vaccine Sales Value by End Users
    • 4.2.1 Global Conjugate Vaccine Sales Value by End Users (2020 VS 2024 VS 2031)
    • 4.2.2 Global Conjugate Vaccine Sales Value, by End Users (2020-2031)
    • 4.2.3 Global Conjugate Vaccine Sales Value, by End Users (%) (2020-2031)
  • 4.3 Global Conjugate Vaccine Sales Volume by End Users
    • 4.3.1 Global Conjugate Vaccine Sales Volume by End Users (2020 VS 2024 VS 2031)
    • 4.3.2 Global Conjugate Vaccine Sales Volume, by End Users (2020-2031)
    • 4.3.3 Global Conjugate Vaccine Sales Volume, by End Users (%) (2020-2031)
  • 4.4 Global Conjugate Vaccine Average Price by End Users (2020-2031)

5 Segmentation by Region

  • 5.1 Global Conjugate Vaccine Sales Value by Region
    • 5.1.1 Global Conjugate Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Conjugate Vaccine Sales Value by Region (2020-2025)
    • 5.1.3 Global Conjugate Vaccine Sales Value by Region (2026-2031)
    • 5.1.4 Global Conjugate Vaccine Sales Value by Region (%), (2020-2031)
  • 5.2 Global Conjugate Vaccine Sales Volume by Region
    • 5.2.1 Global Conjugate Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Conjugate Vaccine Sales Volume by Region (2020-2025)
    • 5.2.3 Global Conjugate Vaccine Sales Volume by Region (2026-2031)
    • 5.2.4 Global Conjugate Vaccine Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Conjugate Vaccine Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Conjugate Vaccine Sales Value, 2020-2031
    • 5.4.2 North America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Conjugate Vaccine Sales Value, 2020-2031
    • 5.5.2 Europe Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Conjugate Vaccine Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Conjugate Vaccine Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Conjugate Vaccine Sales Value, 2020-2031
    • 5.7.2 South America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Conjugate Vaccine Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Conjugate Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Conjugate Vaccine Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Conjugate Vaccine Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Conjugate Vaccine Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Conjugate Vaccine Sales Value, 2020-2031
    • 6.3.2 United States Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Conjugate Vaccine Sales Value, 2020-2031
    • 6.4.2 Europe Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Conjugate Vaccine Sales Value, 2020-2031
    • 6.5.2 China Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Conjugate Vaccine Sales Value, 2020-2031
    • 6.6.2 Japan Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Conjugate Vaccine Sales Value, 2020-2031
    • 6.7.2 South Korea Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Conjugate Vaccine Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Conjugate Vaccine Sales Value, 2020-2031
    • 6.9.2 India Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Conjugate Vaccine Sales Value by End Users, 2024 VS 2031

7 Company Profiles

  • 7.1 Pfizer
    • 7.1.1 Pfizer Company Information
    • 7.1.2 Pfizer Introduction and Business Overview
    • 7.1.3 Pfizer Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Pfizer Conjugate Vaccine Product Offerings
    • 7.1.5 Pfizer Recent Development
  • 7.2 GSK
    • 7.2.1 GSK Company Information
    • 7.2.2 GSK Introduction and Business Overview
    • 7.2.3 GSK Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 GSK Conjugate Vaccine Product Offerings
    • 7.2.5 GSK Recent Development
  • 7.3 Sanofi
    • 7.3.1 Sanofi Company Information
    • 7.3.2 Sanofi Introduction and Business Overview
    • 7.3.3 Sanofi Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Sanofi Conjugate Vaccine Product Offerings
    • 7.3.5 Sanofi Recent Development
  • 7.4 Merck
    • 7.4.1 Merck Company Information
    • 7.4.2 Merck Introduction and Business Overview
    • 7.4.3 Merck Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Merck Conjugate Vaccine Product Offerings
    • 7.4.5 Merck Recent Development
  • 7.5 Walvax Biotechnology
    • 7.5.1 Walvax Biotechnology Company Information
    • 7.5.2 Walvax Biotechnology Introduction and Business Overview
    • 7.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Walvax Biotechnology Conjugate Vaccine Product Offerings
    • 7.5.5 Walvax Biotechnology Recent Development
  • 7.6 Royal (Wuxi) Bio-Pharmaceutical
    • 7.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
    • 7.6.2 Royal (Wuxi) Bio-Pharmaceutical Introduction and Business Overview
    • 7.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Offerings
    • 7.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Development
  • 7.7 Bharat Biotech
    • 7.7.1 Bharat Biotech Company Information
    • 7.7.2 Bharat Biotech Introduction and Business Overview
    • 7.7.3 Bharat Biotech Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Bharat Biotech Conjugate Vaccine Product Offerings
    • 7.7.5 Bharat Biotech Recent Development
  • 7.8 Zhifei Biologic
    • 7.8.1 Zhifei Biologic Company Information
    • 7.8.2 Zhifei Biologic Introduction and Business Overview
    • 7.8.3 Zhifei Biologic Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Zhifei Biologic Conjugate Vaccine Product Offerings
    • 7.8.5 Zhifei Biologic Recent Development
  • 7.9 Beijing Minhai Biotechnology
    • 7.9.1 Beijing Minhai Biotechnology Company Information
    • 7.9.2 Beijing Minhai Biotechnology Introduction and Business Overview
    • 7.9.3 Beijing Minhai Biotechnology Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Beijing Minhai Biotechnology Conjugate Vaccine Product Offerings
    • 7.9.5 Beijing Minhai Biotechnology Recent Development
  • 7.10 SinoPharma
    • 7.10.1 SinoPharma Company Information
    • 7.10.2 SinoPharma Introduction and Business Overview
    • 7.10.3 SinoPharma Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 SinoPharma Conjugate Vaccine Product Offerings
    • 7.10.5 SinoPharma Recent Development

8 Industry Chain Analysis

  • 8.1 Conjugate Vaccine Industrial Chain
  • 8.2 Conjugate Vaccine Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Conjugate Vaccine Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Conjugate Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Conjugate Vaccine Market Trends
  • Table 2. Conjugate Vaccine Market Drivers & Opportunity
  • Table 3. Conjugate Vaccine Market Challenges
  • Table 4. Conjugate Vaccine Market Restraints
  • Table 5. Global Conjugate Vaccine Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Conjugate Vaccine Revenue Market Share by Company (2020-2025)
  • Table 7. Global Conjugate Vaccine Sales Volume by Company (2020-2025) & (Million Unit)
  • Table 8. Global Conjugate Vaccine Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Conjugate Vaccine Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Conjugate Vaccine Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Conjugate Vaccine Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Conjugate Vaccine
  • Table 13. Global Conjugate Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Conjugate Vaccine as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Conjugate Vaccine Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Conjugate Vaccine Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Conjugate Vaccine Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Conjugate Vaccine Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Conjugate Vaccine Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Conjugate Vaccine Sales Volume by Type: 2020 VS 2024 VS 2031 (Million Unit)
  • Table 22. Global Conjugate Vaccine Sales Volume by Type (2020-2025) & (Million Unit)
  • Table 23. Global Conjugate Vaccine Sales Volume by Type (2026-2031) & (Million Unit)
  • Table 24. Global Conjugate Vaccine Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Conjugate Vaccine Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Conjugate Vaccine Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Conjugate Vaccine Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Conjugate Vaccine Sales Value by End Users: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Conjugate Vaccine Sales Value by End Users (2020-2025) & (US$ Million)
  • Table 30. Global Conjugate Vaccine Sales Value by End Users (2026-2031) & (US$ Million)
  • Table 31. Global Conjugate Vaccine Sales Market Share in Value by End Users (2020-2025)
  • Table 32. Global Conjugate Vaccine Sales Market Share in Value by End Users (2026-2031)
  • Table 33. Global Conjugate Vaccine Sales Volume by End Users: 2020 VS 2024 VS 2031 (Million Unit)
  • Table 34. Global Conjugate Vaccine Sales Volume by End Users (2020-2025) & (Million Unit)
  • Table 35. Global Conjugate Vaccine Sales Volume by End Users (2026-2031) & (Million Unit)
  • Table 36. Global Conjugate Vaccine Sales Market Share in Volume by End Users (2020-2025)
  • Table 37. Global Conjugate Vaccine Sales Market Share in Volume by End Users (2026-2031)
  • Table 38. Global Conjugate Vaccine Price by End Users (2020-2025) & (USD/Unit)
  • Table 39. Global Conjugate Vaccine Price by End Users (2026-2031) & (USD/Unit)
  • Table 40. Global Conjugate Vaccine Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Conjugate Vaccine Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Conjugate Vaccine Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Conjugate Vaccine Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Conjugate Vaccine Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Conjugate Vaccine Sales Volume by Region (Million Unit): 2020 VS 2024 VS 2031
  • Table 46. Global Conjugate Vaccine Sales Volume by Region (2020-2025) & (Million Unit)
  • Table 47. Global Conjugate Vaccine Sales Volume by Region (2026-2031) & (Million Unit)
  • Table 48. Global Conjugate Vaccine Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Conjugate Vaccine Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Conjugate Vaccine Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Conjugate Vaccine Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Conjugate Vaccine Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Conjugate Vaccine Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Conjugate Vaccine Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Conjugate Vaccine Sales Volume, (2020-2025) & (Million Unit)
  • Table 56. Key Countries/Regions Conjugate Vaccine Sales Volume, (2026-2031) & (Million Unit)
  • Table 57. Pfizer Company Information
  • Table 58. Pfizer Introduction and Business Overview
  • Table 59. Pfizer Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Pfizer Conjugate Vaccine Product Offerings
  • Table 61. Pfizer Recent Development
  • Table 62. GSK Company Information
  • Table 63. GSK Introduction and Business Overview
  • Table 64. GSK Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. GSK Conjugate Vaccine Product Offerings
  • Table 66. GSK Recent Development
  • Table 67. Sanofi Company Information
  • Table 68. Sanofi Introduction and Business Overview
  • Table 69. Sanofi Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. Sanofi Conjugate Vaccine Product Offerings
  • Table 71. Sanofi Recent Development
  • Table 72. Merck Company Information
  • Table 73. Merck Introduction and Business Overview
  • Table 74. Merck Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Merck Conjugate Vaccine Product Offerings
  • Table 76. Merck Recent Development
  • Table 77. Walvax Biotechnology Company Information
  • Table 78. Walvax Biotechnology Introduction and Business Overview
  • Table 79. Walvax Biotechnology Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Walvax Biotechnology Conjugate Vaccine Product Offerings
  • Table 81. Walvax Biotechnology Recent Development
  • Table 82. Royal (Wuxi) Bio-Pharmaceutical Company Information
  • Table 83. Royal (Wuxi) Bio-Pharmaceutical Introduction and Business Overview
  • Table 84. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Offerings
  • Table 86. Royal (Wuxi) Bio-Pharmaceutical Recent Development
  • Table 87. Bharat Biotech Company Information
  • Table 88. Bharat Biotech Introduction and Business Overview
  • Table 89. Bharat Biotech Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Bharat Biotech Conjugate Vaccine Product Offerings
  • Table 91. Bharat Biotech Recent Development
  • Table 92. Zhifei Biologic Company Information
  • Table 93. Zhifei Biologic Introduction and Business Overview
  • Table 94. Zhifei Biologic Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Zhifei Biologic Conjugate Vaccine Product Offerings
  • Table 96. Zhifei Biologic Recent Development
  • Table 97. Beijing Minhai Biotechnology Company Information
  • Table 98. Beijing Minhai Biotechnology Introduction and Business Overview
  • Table 99. Beijing Minhai Biotechnology Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. Beijing Minhai Biotechnology Conjugate Vaccine Product Offerings
  • Table 101. Beijing Minhai Biotechnology Recent Development
  • Table 102. SinoPharma Company Information
  • Table 103. SinoPharma Introduction and Business Overview
  • Table 104. SinoPharma Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 105. SinoPharma Conjugate Vaccine Product Offerings
  • Table 106. SinoPharma Recent Development
  • Table 107. Key Raw Materials Lists
  • Table 108. Raw Materials Key Suppliers Lists
  • Table 109. Conjugate Vaccine Downstream Customers
  • Table 110. Conjugate Vaccine Distributors List
  • Table 111. Research Programs/Design for This Report
  • Table 112. Key Data Information from Secondary Sources
  • Table 113. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Conjugate Vaccine Product Picture
  • Figure 2. Global Conjugate Vaccine Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Conjugate Vaccine Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Conjugate Vaccine Sales Volume (2020-2031) & (Million Unit)
  • Figure 5. Global Conjugate Vaccine Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Conjugate Vaccine Report Years Considered
  • Figure 7. Global Conjugate Vaccine Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Conjugate Vaccine Players Sales Volume Ranking (2024) & (Million Unit)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Conjugate Vaccine Revenue in 2024
  • Figure 10. Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Hib Vaccine Picture
  • Figure 12. Meningococcal Vaccine Picture
  • Figure 13. Pneumococcal Vaccine Picture
  • Figure 14. Others Picture
  • Figure 15. Global Conjugate Vaccine Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Conjugate Vaccine Sales Value Market Share by Type, 2024 & 2031
  • Figure 17. Global Conjugate Vaccine Sales Volume by Type (2020 VS 2024 VS 2031) & (Million Unit)
  • Figure 18. Global Conjugate Vaccine Sales Volume Market Share by Type, 2024 & 2031
  • Figure 19. Global Conjugate Vaccine Price by Type (2020-2031) & (USD/Unit)
  • Figure 20. Product Picture of Children
  • Figure 21. Product Picture of Adult
  • Figure 22. Global Conjugate Vaccine Sales Value by End Users (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 23. Global Conjugate Vaccine Sales Value Market Share by End Users, 2024 & 2031
  • Figure 24. Global Conjugate Vaccine Sales Volume by End Users (2020 VS 2024 VS 2031) & (Million Unit)
  • Figure 25. Global Conjugate Vaccine Sales Volume Market Share by End Users, 2024 & 2031
  • Figure 26. Global Conjugate Vaccine Price by End Users (2020-2031) & (USD/Unit)
  • Figure 27. North America Conjugate Vaccine Sales Value (2020-2031) & (US$ Million)
  • Figure 28. North America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Europe Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Asia Pacific Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Asia Pacific Conjugate Vaccine Sales Value by Region (%), 2024 VS 2031
  • Figure 33. South America Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. South America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Middle East & Africa Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Middle East & Africa Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Key Countries/Regions Conjugate Vaccine Sales Value (%), (2020-2031)
  • Figure 38. Key Countries/Regions Conjugate Vaccine Sales Volume (%), (2020-2031)
  • Figure 39. United States Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. United States Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 41. United States Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 42. Europe Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Europe Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Europe Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 45. China Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. China Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 47. China Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 48. Japan Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Japan Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Japan Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 51. South Korea Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. South Korea Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 53. South Korea Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 54. Southeast Asia Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. Southeast Asia Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 56. Southeast Asia Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 57. India Conjugate Vaccine Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. India Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • Figure 59. India Conjugate Vaccine Sales Value by End Users (%), 2024 VS 2031
  • Figure 60. Conjugate Vaccine Industrial Chain
  • Figure 61. Conjugate Vaccine Manufacturing Cost Structure
  • Figure 62. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 63. Bottom-up and Top-down Approaches for This Report
  • Figure 64. Data Triangulation
  • Figure 65. Key Executives Interviewed